Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-03-20
2007-03-20
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S015800, C514S016700, C514S017400, C530S327000, C530S328000, C530S329000, C530S330000
Reexamination Certificate
active
09202305
ABSTRACT:
The present invention provides peptides which affect T-cells, presumably by action on the T-cell antigen receptor. The present invention further relates to the therapy of various inflammatory and autoimmune disease states involving the use of these peptides. Specifically, the peptides are useful in the treatment of disorders where T-cells are involved or recruited. In one aspect the peptides have the formula: R1-A—B—A—R2 in which A is a hydrophobic amino acid or a hydrophobic peptide sequence comprising between 2 and 10 amino acids; B is a charged amino acid; R1 is NH2 and R2 is COOH. In another aspect the peptides have the formula: R1-A—B—C—R2 in which A is a peptide sequence of between 0 and 5 amino acids; B is cysteine; C is a peptide sequence of between 2 to 10 amino acids; R1 is NH2; and R2 is COOH.
REFERENCES:
patent: 5936065 (1999-08-01), Arrhenius et al.
patent: 432691 (1991-06-01), None
patent: 0 443 404 (1991-08-01), None
patent: 0 443 404 (1991-08-01), None
patent: 91/09613 (1991-07-01), None
patent: WO 94/020127 (1993-04-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 95/07707 (1995-03-01), None
patent: WO 95/26980 (1995-10-01), None
patent: WO 95/26980 (1995-12-01), None
patent: WO 95/34312 (1995-12-01), None
patent: WO 96/03140 (1996-02-01), None
patent: WO 96/22306 (1996-07-01), None
Ngo et al., ‘Computational Complexity, Potein Structure Prediction, and the Levinthal Paradox,’ The Protein Folding Problem and Tertiary Structuer Prediction. Ed. K. Merz and L. Le Grand. BirkHauser, Boston MA. pp. 491-495. 1994.
Rudinger, J. (1976). Peptide Hormones (ed. J.A. Parsons). University Park Press. Baltimore. pp. 1-7.
Kagan et al. ‘Influence of Sequence and Charge on the Specificity of Lysyl Oxidase Toward Protein and Synthetic Peptide Substrate’, J. Of Biol. Chem. vol. 259, No. 18, pp. 11203-11207, Sep. 1984.
Supplemental Euroean Search Report EP 97 92 4813.
Vijay K. Kuchroo et al., “A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoire”, The Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, vol. 153, No. 7, Oct. 1, 1994, pp. 3326-3336.
Stephen C. Jameson et al., “Clone-specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-restricted Cytotoxic T Cells”, Journal of Experimental Medicine, Tokyo, Japan, vol. 177, No. 6, Jun. 1, 1993, pp. 1541-1550.
K. Hogquist et al., “T Cell Receptor Antagonist Peptides Induce Positive Selection”, Cell, Cell Press, Cambride, NA, US, vol. 76, No. 1, Jan. 14, 1994, pp. 17-27.
Shuji Ikagawa et al., “Single Amino Acid Substitutions on a Japanese Cedar Pollen Allergen (Cry┘ 1)- derived Peptide Induced Alterations in Human T Cell Responses and T Cell Receptor Antagonism”, Journal of Allergy and Clinical Immunology, Mosby—Yearly Book, Inc. US, vol. 97, No. 1, part 1, Jan. 1996, pp. 53-64.
Geoffrey A. Cole et al., “T Cell Recognition of the Immunodominant Sendai virus NP324-332/Kb epitope is focused on the center of the Peptide”, Journal of Immunology, Coden: JOIMA3; ISSN: 0022-1767, vol. 155, No. 6, Sep. 15, 1995, pp. 2841-2848.
M. Oldstone et al., “Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection”, Journal of Virology, The American Society for Microboiology, U.S. vol. 69, No. 12, Dec. 1, 1995, pp. 7423-7429.
Nathan Karin et al., “Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production”, Journal of Experimental Medicine, Tokyo, JP, vol. 180, No. 6, Dec. 1, 1994, pp. 2227-2237.
M. Teresa De Magistris et al., “Antigen Analog-Major Histocompatibility Complexes Act As Antagonists of the T Cell Receptor”, Cell, vol. 68, No. 4, Feb. 21 1992, pp. 625-634.
N.S. Shimizu et al., “Inhibition of infection of T-cells with human immunodeficiency virus type 1 by dideoxynucleosides conjugated with oligopeptides”, Antiviral Chemistry and Chemotherapy (1995) 6(1), pp. 17-24.
Bernard Mari et al., “Thrombin and trypsin-induced Ca2+ mobilization in human T cell lines through interaction with different protease-activated receptors”, FASEB Journal, CODEN: FAJOEC: ISSN: 0892-6638, vol. 10, No. 2, Feb. 1996, pp. 309-316.
Bjorn R. Gundlach et al., “Determination of T cell epitomes with random peptide libraries”, Journal of Immunological Methods, CODEM: JIMMBG; ISSN: 0022-1759, vol. 192, No. 1-2, Jun. 10, 1996, pp. 149-155.
Thomas C. Manning et al., “A strategy for the synthesis and screening of thiol-modified peptide variants recognized by T cells”, Journal of Immunological Methods, CODEN: JIMMBG; ISSN: 0022-1759, vol. 192, No. 1-2, Jun. 10, 1996, pp. 125-132.
Irma Joosten et al., “Direct binding of autoimmune diseases related T cell epitopes to purified Lewis rat MHC class II molecules”, International Immunology, CODEN: INIMEN; ISSN: 0953-8178, vol. 8, No. 5, May 1994, pp. 751-759.
Peter G. Livingston et al., “Dengue virus-specific, HLA-B35-restricted, human CD8+ cytotoxic T lymphocyte (CTL) cloes. Recognition of NS3 amino acids 500 to 508 by CTL clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities”, Journal of Immunology, CODEN: JOIMA3; ISSN: 0022-1767, vol. 154, No. 3, Feb. 1, 1995 pp. 1287-1295.
Manolios et al. “T-cell Antigen Receptor Transmembrane Peptide Modulate T-cell Function and T-cell Mediated Disease”Nature Medicine3(1):84-88, Jan. 1997.
International Search Report.
Vijay K. Kuchroo et al., “A Single TCR Antagonist Peptide Inhibits Experimental Allergic Encephalomyelitis Mediated by a Diverse T Cell Repertoir”, The Journal of Immunology, The Williams and Wilkins Co., Baltimore, US, vol. 153, No. 7, Oct. 1, 1004, pp. 3326-3336.
S.C. Jameson et al., “Clone-Specific T Cell Receptor Antagonists of Major Histocompatibility Complex Class I-Restricted Cytotoxic T Cells”, Journal of Experimental Medicine, Tokyo, Japan, vol. 177, No. 6, Jun. 1, 1993, pp. 1541-1550.
K.A. Hogquist et al., “T Cell Receptor Antagonist Peptides Induce Positive Selection”, Cell, Cell Press, Cambridge, NA, US, vol. 76, No. 1, Jan. 14, 1994.
N. Karin et al., “Reversal of Experimental Autoimmune Encephalomyelitis by a Soluble Peptide Variant of a Myelin Basic Protein Epitope: T Cell Receptor Antagonism and Reduction of Interferon Gamma and Tumor Necrosis Factor Alpha Production”, Journal of Experimental Medicine, Tokyo, JP, vol. 180, No. 6, Dec. 1, 1994, pp. 2227-2237.
M. T. De Magistris et al., “Antigen Analog-Major Histocompatiblity Complexes Act as Antagonists of the T Cell Receptor”, CELL, vol. 68, No. 4, Feb. 21, 1992, pp. 625-634.
Foley & Lardner LLP
Gupta Anish
Northern Sydney & Central Coast Area Health Services
LandOfFree
T cell antigen receptor peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with T cell antigen receptor peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and T cell antigen receptor peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3802795